What ReNeuron Group does

ReNeuron Group Limited is a UK-based biotechnology company developing exosome-based drug delivery systems. Founded in 1997 by Dr John Sinden at King's College London, the company originally advanced cell-based therapies for stroke disability and retinitis pigmentosa, but out-licensed both clinical programmes to Fosun Pharma in 2019 and pivoted in 2022 to focus on stem-cell derived exosomes for targeted therapeutic delivery. Its core offering is the CustomEX™ platform — a biologically driven, scalable exosome delivery system built on four proprietary neural stem cell lines, three proprietary stem cell lines, and conditionally immortalised iPSCs (CI-iPSCs) that produce exosomes with innate tissue-targeting properties and well-characterised biological profiles. The platform is positioned to deliver RNA, proteins, and small molecule therapeutics and to traverse biological barriers including the central nervous system, without reliance on synthetic modification or post-production engineering.

The company's revenue model combines three streams: licensing/out-licensing arrangements for clinical programmes, distribution of its legacy ReNcell CX and VM immortalised human neural stem cell lines through Sigma-Aldrich, and strategic research partnerships that fund research associate positions. CustomEX™ itself is monetised through co-development deals (e.g., Laverock Therapeutics for in-vivo gene therapy) and academic research collaborations (e.g., Swansea University), rather than through direct sales. The company is led by Chairman Iain Ross, Managing Director & CSO Dr Randolph Corteling, and Finance Director Keith Parrish, with a headcount in the 11–50 range.

ReNeuron exited administration in March 2025 and re-launched as a private company focused on stem cell line development expertise, transitioning from its previous public-company structure on the London Stock Exchange. Its registered office is in Weybridge, Surrey, and a new operational base was established at Swansea University's Institute of Life Science in March 2026 to advance exosome research. There is no disclosed revenue figure in the source material, and the company's near-term value creation depends on converting CustomEX™ partnerships into licensing or co-development economics.

Name

ReNeuron Group

Legal name

ReNeuron Group Limited

Website

https://reneuron.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

ReNeuron Group is a UK-based private biotechnology company that develops the CustomEX™ exosome delivery platform, built on proprietary conditionally immortalised stem cell lines, to enable targeted delivery of RNA, proteins, and small molecule therapeutics to pharmaceutical, gene-therapy, and academic research customers.

Ownership category

akta.pro rank

Product category

Exosome Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Neural & Spinal Cord Regeneration (HLAAAGAI)

Keywords

• Exosome therapeutics
• Stem cell technology
• Targeted drug delivery
• Precision medicine
• Cell-based therapies

Headquarters

HQ city

Guildford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Out-licensing of Clinical Programmes: ReNeuron out-licensed its stroke and retinitis pigmentosa clinical programmes to Fosun Pharma in 2019, representing a licensing revenue stream from prior clinical development investments.
2. Stem Cell Line Sales: ReNcell CX and VM immortalised human neural stem cell lines are available for purchase through Sigma-Aldrich distribution, generating research product revenue.
3. Research Partnerships: Strategic research collaborations with academic institutions that include funding for research positions and laboratory resources, supporting R&D activities.

Distribution channels2 records

Marketing channels4 records

Core offering

ReNeuron develops and commercialises the CustomEX™ platform — a biologically driven, scalable exosome delivery system built on proprietary conditionally immortalised stem cell lines and induced pluripotent stem cells (iPSCs). The platform produces a tailored catalogue of exosome types with distinct tissue tropisms for targeted delivery of RNA, proteins, and small molecule therapeutics, including traversal of biological barriers such as the central nervous system. The company also sells legacy ReNcell CX and VM neural stem cell lines via Sigma-Aldrich.

Product overview

ReNeuron is a biotechnology company that has pivoted from cell-based therapies to exosome-focused therapeutics. The core offering is the CustomEX™ platform—a biologically driven, scalable exosome delivery system built from proprietary conditionally immortalised stem cell lines and iPSCs. The platform produces a library of exosome types, each derived from distinct stem cells with specific tissue tropisms. ReNeuron also commercialises legacy neural stem cell line products (ReNcell CX and VM) available through Sigma-Aldrich. The CustomEX™ platform enables targeted delivery of RNA, proteins, and small molecule therapeutics, with capabilities for traversing biological barriers including the central nervous system.

Differentiator

Problem solved

Functional benefit

Brands

• CustomEX™: Proprietary customizable exosome platform built from engineered stem cells, designed for targeted therapeutic delivery and precision medicine applications.

Products and services

• CustomEX™ Platform A biologically driven, scalable exosome delivery system built from proprietary conditionally immortalised stem cell lines and iPSCs. Enables consistent production of high-quality exosomes with well-characterised biological properties and innate tissue-targeting capabilities for pharmaceutical and biotechnology partners.
• ReNcell CX and VM Immortalised human neural stem cell lines developed by ReNeuron and made available for purchase through Sigma-Aldrich for research use. Forms part of the company's legacy research product portfolio.
• CI-iPSC (Conditionally Immortalised iPSC) Conditionally immortalised induced pluripotent stem cells used as producer cell lines for generating exosomes with specific therapeutic applications within the CustomEX™ platform.

Quantifiable outcome

• World's first clinical trial for conditionally immortalised stem cell therapy for stroke disability
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Swansea UniversitycoreStrategic or Co-development Partner · 19 March 2026ReNeuron established a new operational base at Swansea University's Institute of Life Science in South Wales through a strategic research partnership to advance exosome therapies using its CustomEX™ platform. The collaboration combines Swansea's laboratory facilities and research expertise with ReNeuron's proprietary stem-cell-derived exosome producer lines to develop delivery vehicles for transporting therapeutic cargo to hard-to-reach organs and cell types. The partnership funds a full-time research associate position and aims to progress biotechnological innovations from laboratory research toward clinical and commercial application.
• Laverock TherapeuticscoreStrategic or Co-development Partner · 7 January 2026Strategic collaboration to develop in-vivo gene therapies, combining ReNeuron's exosome delivery capabilities with Laverock Therapeutics' gene therapy expertise.
• Sigma-AldrichminorChannel Partner/ Reseller/ DistributorReNcell CX and VM immortalised human neural stem cell lines developed by ReNeuron are available for purchase through Sigma-Aldrich's commercial distribution network, making them accessible to researchers globally.

Scale indicators2 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• BrainStorm Cell Therapeutics: Clinical-stage developer of autologous cell therapies (NurOwn®) for neurodegenerative diseases including ALS and MS. Comparable to ReNeuron's earlier cell therapy focus (stroke, retinitis pigmentosa) and CNS-targeted approach.
• Athersys: Clinical-stage biotechnology company developing MultiStem® cell therapies for stroke, ARDS, and other indications. Directly comparable to ReNeuron in the historic cell-therapy-for-stroke space and a cautionary comparable given its own financial restructuring and clinical setbacks.
• Capricor Therapeutics: US clinical-stage biotechnology company developing cell-derived therapeutics (cardiosphere-derived cells and exosomes) for Duchenne muscular dystrophy and other indications. Comparable to ReNeuron as a cell-derived biologic/exosome developer with CNS and rare-disease focus.
• Codiak BioSciences: US-based clinical-stage company engineering exosomes (engEx™) for therapeutic use in oncology and other indications. Directly comparable to ReNeuron's CustomEX™ platform as a developer of engineered exosome-based drug delivery systems, although Codiak is more advanced clinically.
• Evox Therapeutics: UK-based biotechnology company developing exosome-based therapeutics for the delivery of RNA, protein, and small molecule drugs to hard-to-reach tissues. Directly comparable to ReNeuron as a fellow exosome-delivery platform company targeting CNS and other difficult indications.

Emerging players

• ExoCoBio: South Korea-based exosome therapeutics and regenerative medicine company, focused on stem cell-derived exosomes for cosmetic and therapeutic applications. Overlaps with ReNeuron on the stem cell-derived exosome production approach, though primarily a regional/scale-up player.
• Celularity: Clinical-stage cell therapeutics company using placenta-derived cells and exosomes for oncology, immunology, and regenerative medicine. Comparable to ReNeuron's pivot toward exosome-based delivery and cell-derived therapeutics, though with a different cell source.

Broad incumbents

• Mesoblast: Commercial-stage cellular medicines company with approved products (Remestemcel-L) and a broad pipeline in inflammatory and cardiovascular diseases. A larger incumbent in the cell-based therapeutics space adjacent to ReNeuron's historical and emerging exosome focus.
• Stemcell Technologies: Major supplier of stem cell research tools, cell culture media, and primary cell products. Comparable to ReNeuron via its legacy ReNcell CX/VM distribution through Sigma-Aldrich, representing the research-tools side of the stem cell market.

Peers

• Pluristem Therapeutics:

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/todd55marsh
• LinkedInlinkedin.com/company/reneuron

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReNeuron Group